Predictors of defibrillation efficacy in patients undergoing epicardial defibrillator implantation  by Leitch, James W & Yee, Raymond
Predictors of Defibrillation Efficacy in Patients Undergoing Epicardial 
Defibrillator Implantation 
JAMES W. LEITCH, MB, BS, RAYMOND YEE, MD, FACC* AND THB MULTIC~.VTER PACEMAKER- 
CARDIOVERTER-DEFIBRILLATOR (PCD) INVESTIGATORS GROUPS 
Newcasrle, New South Wales, Australia md London, Ontario, Canada 
Objectives. The objective ol this study ma to identify prcdk- 
tars Op drRbrlUaUon threshold in palionk undergoing opkmdkl 
bfibrilklor impkntatiin. 
Buckgnmd. Fadors that predkl epknrdiel dtibrlllalion elli. 
CUCEY are worlv defined. 
kth& The data from 315 conseedive adult patknk were 
revkwed. AltDr exefusion of 137 patients In wham ddIbrilkIion 
lhreshold w&8 not oblabed, 238 ptknts (32 worn and 206 na) 
dlh P mean age of 58.9 f 13.3 years tonne4 the study grwp. 
Coronary hearl disease was p&t in 175 pptknts so4 lhe mean 
iep( venlrieular ejecllon fraetlon was 35.8 * 15.4%. At devil 
implsnt&on, three epkardkl patch siu were avaikbk and 
shocks mukl be delivered over one eorreot pnlhway (two patches) 
or over two forrent mdhwws (Ihree pstchs with shnullaneow or 
rzquentkl shocks). ~DelkRbr&tion threshold wa delined 8s tbe 
lowest programmed energy that sucewfully dellbrilIs!ed the 
heart, provided there had ken an unswessful shack al a lower 
wrrgy level or surcssful defibrillstian at r5 J. 
RrruuI. The mean daibrllktkn tbr&oM WPF 8.6 f 5.3 1. 
With univarkte analysis, fern& gender, sequsnlial sharks with 
three patches, hi&r I& vcntrkulpr ejeetiin frtiirm and 
lower New York Heart Aweiatii functIonal claw predkted 
P kwer d&rillatIon lhrabdd. In Ihe multivsrlak analysb, 
female gender (caclliclmt -3.9; 95% eonlidew interval [CII 
-1.9 to -5.0 J), ejeeIlim frllctii (at -0.e CI -0.1 
to -1.0 J/d&) an4 zqaalii skxks (m&kknt -2.5: Cl -1.0 
to -4.0 J) were indepwkotly eaaiated wkh a kver defihri0n- 
Iion tire&old. Total rplandia p&h conductive surfam area 
nonnrlked lo Iwly wrface arew raebed b@rderlim ?&&kae 
(c&&r4 O.op1; CI 0 la 0.01; p = 0.10). An~7thmk dng 
use, iwIlding amkdamne, did nd predkl dcMhrlUatbn thr&- 
old. 
ConcluEionr Femak gender, high Idt ve,&kukr ej&ioo 
fraellon and the me ol sqxential pke sb&s were impor(sPt 
4eierminsnls of impmwd d&rlIktlorl dbewy. 
(J Am Cdl Cm&l 1993;21:1432-1) 
Defibrillation threshold determined during defibrillator im- 
plantation does not seem to be predictable in the individual 
patient (I). The only clinical factors shown to affect defibril- 
lation threshold at device implantation have been amio- 
darone use (I) and myocardial mass (2). Prior knowledge of 
defibrillation threshold would facilitate the allocation of 
patients to nonthomcotomy systems (2-6) and help in the 
choice of defibrillation patch size and hardware during 
epicardial implantation (I.FIO). Failure of previous studies 
to find r*her clinical predictors of defibrillation threshold 
may relate to the maiked variability in this measurement 
(I l-13) in combination with the relatively small number of 
patients studied (1.2). ‘The interaction between clinical varl- 
ables such as cardiac function and technical factors such as 
patch size may also relder interpretation of the results 
di0Icult. We sought to overcome Some of these problems by 
studying a large multicenter series of patients undergoing 
defibrillator implantation with epicardial leads, with the aim 
of elocidatina the clinical and technical factors associated 
with internaldefibrillation efficacy. 
Consecutive patients undergoing implantation of a model 
7216 or 7217 Medlronic defibrihator id the participating 
centers (see Appendix) were included in this study. Patients 
were excluded if their age was <I6 years or if transvenous 
electrodes or subcutaneous patches were used. The data 
wrre obtained from the centralized data base maintained by 
the manufacturer of the device after agreemenl from the 
participating centers. 
B&t implantation. After !horacotomy and fixation of 
the pacing and sensing leads, two or three oval platinum 
alloy electrode coil defibrillation patches were sutured to the 
heart. Three defibrillation patch sizes were available with 
conductive sorface areas of 370, 640 and 840 mm2 
(Medtronic model 6921% 6291M and 629lL, respectively). 
The compxents of the defibrillator system, including the 
number, size and location of patches and the type of shock 
delivered, we:c dc!crxined by the implanting physician. 
Patch location and polarity varied considerably among the 24 
participating centers. Generally, with a two-patch system, 
one patch was sutured to the posterior leit ventricle and the 
other to the anterior right ventricle. With a three-patch 
system. patches were generally placed at the left ventricular 
apex. anrerior right rrntricle and posterior septum toward 
the base of the heart. When three patches were present, 
either seqtiential or simultaneous shocks could be delivered 
over the two current pathways. in practice. however, almost 
all (121 of the 126) patients with three patches had sequential 
shocks. With sequential and simultaneous shocks, stored 
energy was divided equally over the two current pathways. 
The applied energy therefore varied slightly between the two 
pathways, depending on their relative impedance. 
For sin& or simultaneous shocks. a &cad enponeo- 
tially decaying waveform with a mdse width of 6.3 ms was 
used. Sequen&l shocks had a p&e width of 3.9 ms sepa- 
rated by 2 ms (in some cases, pulse width was not fixed but 
was dependent on the 6(% tilt waveform). Defibrillation 
testing was performed with an external defibrillator 
(Medtronic model 5355) that recorded peak voltaxe, correct, 
impedance and stored and applied e&y for each shock. 
Stored energy for xch shock could be programmed in I-J 
increments. Before defibrillation testing. a shock ofO.6J was 
delivered to test the integrity of the defibrillation pathways 
(14,. >. .,. 
Pmtoml for deRbrillatlon testing. The protocol for deft- 
hrillation testing was as hollows. A shock with stored energy 
of I8 J was delivered mawally after IO to IS s of induced 
ventricular fibrillation. If this was successful. further shocks 
of IS. 10 and 5 1 were delivered during separate fibrillation 
episodes. Subsequent testing with further decrement in the 
defibrillation energy was pafwmed at the discretion of the 
implanting physician. This protocol could be v&d. depend- 
ing on clinical circumstances. Three successful shocks at 
stored energy levels of ml8 J were generally required for 
implantation. For this study. defibrillation thres’hold was 
defined as the lowest enerev level that successfullv delibril- 
lated the heart, provided th&e had been at leas: one U~EUC- 
cessful shock at a lower energy level or success bad been 
achieved at a level oP ~5 .I. Success was defined as a 
postshock rhythm other than ventricular fibrillation. vemric- 
ular flutter or ventria.!ar tachycardia. Only the first shock 
delivered doting a fibrillation episode was used in this 
analysis. 
A defibrillation threshold, as defined, war not available m 
I37 of 375 eligible patients. typically because 1) induction of 
Bbdllation was stopped after three socces~es (never having a 
Failure or delivering energies s5 I), Z‘I inability to induce 
ventricular fibrillation. and 3) termination of testing before 
three socces~es because of det+&ating patient condition. 
Patients in whom defibrillation threshold was obtained did 
not diier in age, gender or cardiac function fmm patients in 
whom a defibrillation threshold was not obtained: however, 
Table 1. Cowarison of Patients With and Without a 
Defihnllat~on Threshaid 
the two groups d&red in the use of sequential shocks and 
frequency of amiodamne use (Table I). 
In the ?38 study patients. ejection fraction was measured 
by radionuclide angiography in 194 patients and by contrast 
ventricologropny in 44 pat;ents. C&onory aogiogiaphy was 
paformed in all patients and the presence of coronary 
disease was defined as a lesion ~40% diameter in a major 
coronary artery. Eighty-two patients were taking antiar- 
rhythmic medication at the time of defibrillation testing: 
most commonly this was amiodamne (38 patients). 
Data analysis. Freauencies were compared with the chi- 
sqwre test and contiamus variables with unpaired t tests. 
Multiple linear regression was used to determine pxdiitors 
of the deAbrillation threshold. Variables included in this 
analysis 60 listed in Table 2 and were excluded in a 
backward step&e fashion if the p value was > 0.10. 
RLXdtS 
The mean defibrillation threshold for the 238 patients was 
8.6 e 5.3 J (median X.5) (Fig. I). Female gender, the use of 
three patches with sequential shocks, higher ejection frac 
tion and lower Nw York Heart Association functional class 
were all ass&&d with a lower delihrillation tireshold 
(Tah!c 2). The median deiibri:lation threshdd was 5 J with 
sequential shocks compared with IO I without sequential 
shocks (Fig. 2). Figure 3 shows the variation in delIbrillation 
threshold according to ejection fraction. A higher delibrilla- 
tion threshold was seen primarily in those paiients with a 
very low ejection fraction. 
There was no association between defibrillation thresbo:d 
sod either body surface area or the total conductive surfwe 
area of the defibrillation patches. When patch conductive 
surface area was notmalized for body size by dividing by 
Tat k 2. LInivtiate Predictors of Defibrillation Tbresbotd in the 
138 Stud” Patients 
body surface area, there was still no association with defi- 
brillation threshold. Defibrillation threshold did not vary 
with the type of cardiac disease present (defibrillation 
threshold with coronary artery disease 8.6 + 5.4 J and with 
dilated cardiomyopathy 9.4 + 5.4 J, p = 0.23). nor was 
defibrillation threshold influenced by whether concomitant 
cardiac surgery (such as coronary artery bypass surgery) 
was performed at the time of defibrillator implantation. 
Except for amiodarone, antiarrhythmic medications were 
used infrequently (Table 2). Only the use of mexiletine was 
significantly related to defibrillation threshold (p = 0.04). 
Multivariate analysis. Female gender, the use of sequen- 
tial shocks (or the use of thwc patches) and ejection fraction 
Figure t. Frequency histogram of defibrillation threshold in the 238 
study patients. 
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Figure 3. Box plots of defibrillation threshold with sequential (Seq) 
and single shocks. The aswi& indicate the median value and the 
beada& oftbe bar represent he interquartile range. There was a 
significant di!Terence between sequential and single shocks tp < 
lMltJI). 
were all inversely associated with detibtillation thrcsbold in 
the multivariate analysis (Table 3). Defibrillation patch SW 
face area normalized to body surface area reached border- 
line significance. No other variable significantly improved 
the fit of this model. The coefficient for sequential shocks 
was 2.5 I (95%contidence interval I.0 to4.OJ). suggesting an 
average decrease in dellbrillation threshold of >2 J with this 
techniaue. 
DiSCUSSiOll 
Measurement of the defibrillation threshold is dicult in 
patients undergoing defibrillator impIant&n because of the 
inherent variability in this measurement (11-13). Ideally, 
multiple defibrillation trials should be peffornzd in each 
patient and an averaging technique used to estimate the 
probability of the “defibrillation threshold” (11-W. This is 
not feasible at the time of defibrillator implantation, when 
the number of fibrillation episodes is lhnited. To overcome 
the variability in this measurantent. we studied a lame 
number of pa&& and found several clinical and techni& 
factors that were associated with defibrillation efficacv. In 
these study patients, the most important of these fa&rs 
were gender, ejection fraction and the use of three patches 
with sequential shocks. 
Sequential shacks. It is not w’prising (hat sequential 
shocks were associated with a lowar defibrillation threshold 
in view of the consistent benefit from the defibrillator tech- 
nique in smaller human and animal studies (3,15-17). Be- 
catw nearly all patients with three patches had sequential 
rather than simultaneous shocks, it was not possible to 
evaluate the use of three patches and sequential shwks 
separately. A previous study (18) demonstrated that sequep 
tial shocks improve defibtili:&n efficacy compared with a 
single pulse delivered ow :hr same current pathways. 
In contrast to previous studies (1.11-13). defibrillation 
patch conductive swfac area was not clearly related to 
defibrillation threshold. One possible reason for this is that 
the implanting surgeons attempted to match the size of the 
deAbritk&m patches to the size of the heart. Therefore, the 
ratio between patch area and heart mass, which would be 
expected to influence defibrillation threshold (1,2,19), may 
Figure 3. Box plot of defibti!!ation threshold by ejec- 
*ion fraction cm, in deciks,. BOX p,o,a as in Figure 1. 
The nar:bers indicate outtying valuer. There was a 
si&cant relation between defibrillation threshold 
and ejection fraction (p = 0.02). 
have remained relatively conrtant. In the multiva&te an+ 
ysis, patch surface area norm&cd to bodv surface area did 
reach borderline significance. 
Ejectian irsrtion. Ejection fraction, measured by nd’o 
nuclide angiogmphy in 82% of patients and by contmnt 
ventriculogmphy in 18% of patients, was inversely BSSLXI- 
ated with defibrillation threshold. Despite achieving statisti 
ccl significance, this relation was weak and predocdnawly 
due to high thresholds in patients with a very low ejectwn 
tiaction and vice versa. For the majority of patients with an 
eiection fraction between 20% and MB. the defibtillatir~ 
threshold appeared to vary little with changes in cjectbn 
fraction. Unfortunately. measurements of myowdial mass 
and absolute volume, which may have predicted defibrilla- 
lion threshold better (2,lY). were not available. 
Gender. LIefibrillation threshold w’cs clearly lower in 
female patients. This finding is in accord with a recent study 
(20) of patients with a high detitril:ation threshold. 93% of 
whom were male. There were many di@erences betwreo 
male attd female patients that might have led to thi$ finding 
(Table 4). However, even after adjusting for these factors, 
female gender renuined hiily significant (Table 3). Cnc 
possible explanation is that detibrillation threshold is inher- 
ently lower in women than in men. A more probable exp’a- 
nation is that there were unmeasured variables associxed 
with gender that are important to defibrillation etfi~a-~: and 
were not accounted for in the multirtiatr anaivais. 
Antiarrh@xnic medication. The powet to detect the if- 
fects of medication was limited by the relatively small 
number of patients taking each medication and by the use of 
multiple medications by some patients. Many factors were 
:ested for their association with defibrillation threshold (Tam 
ble 2) and the clinical significance of a p valve of 0.04 found 
for mexiletine is uncertain. Furthermore. m dmgs with a 
short half-life, serum levels are likely to have varied consid- 
erablv at the time of defibrillation tesfina This latter factor 
should not confound the effect of andodamne. which in 
contrast to other studies (1.20-22). did nor substantially 
infiuence defibrillation threshold. However, it is oossible 
that some patients not taking amiodarone at the’titne of 
implantation had taken it in lhe months before implantation. 
This might diminish the apparent effect of an&&one on 
defibrillation threshold. -- 
Limitations. The choice cf the defibrillator system, in- 
cluding the type of shocks and the number and size of the 
patches, was not randomized and retlected individual physi- 
cian beliefs as to the value of sequential shocks and two 
current pathways. Hence, selection hias may have system- 
atically affected the results of the study. In some cases, 
sequential shocks may have been reserved for use in patients 
with B known or suspected high defibrillation threshold. This 
practice would tend to lessen the inverse association be- 
tween defibrillation threshold and sequential shocks. There- 
fore, selection bias is unlikely to be responsible for this 
finding. Furthermore, the magnitude of the difference in 
defibril!atioh threshold between sew&al and sin& shocks 
(about 2.5 J) is consistent with a p&ms random&d study 
(16) comparing similar types of shocks in humans. 
The patients in our study underwent defibrillation implan- 
tation in many different centers where deftbrillnion t&sting 
may have varied, derendim? on clinical circumstances. The 
da& were obtained r&osp&ively from a database that was 
not designed for this study and it was therefore not pwsible 
to control for variables such as fibrillation time. type of 
anesthesia and other factors that may influence defibrillation 
threshold (23-29). 
Impliitionv. Despite these limitations, several factors 
did emerge as important predictors of defibrillation efficacy. 
Although the relation between defibrillation threshold and 
clinical factors such as ejection fraction was not sticiently 
strong to be helpful in indivi ‘MI patients. this study dem- 
onstrates that myocardial function does Muence defibrilla- 
tion eilicacy. Fufth.er studier, perhay; involving more pre- 
cise quantification of myocardir! function and size, may 
allow better prediction nf !be defibrillation threshold. 
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